EpiGlioT | Epigenetic Glioblastoma Therapeutics

Summary
The goal of this project is to develop a successful treatment that combats the progression of glioblastoma and improve patients’ quality of life. Glioblastoma, the most malignant brain tumour, leads to disproportionately high morbidity in patients and impacts the economy through high mortality rates. The available treatment options are highly ineffective and pose a significant challenge to the healthcare budgets of all nations.

Beactica aims to address this challenge by developing novel compound to inhibit the overexpressed in cancers protein LSD1. Beactica’s programme is based on a verified LSD1 knockdown technique and proves markedly more effective with glioblastoma clones that are resistant to other therapeutics. This way, Beactica’s compounds effectively clear cancer cells from which brain tumour might grow anew and will reduce the risk of relapses.

This therapy will improve intervention outcomes for patients and lower additional treatment and healthcare costs including longer hospitalisation and further medical procedures. This programme is unique and there are no competitors using the same approach to treat glioblastoma by knockdown of the LSD1 protein with a small molecule.

The ultimate success of this project will depend on the generation of clinical data which will improve opportunities for out-licensing. Beactica plans to apply for SME Phase 2 grant to take the lead compound through the clinical Phase I/IIa, and then reach the pharmaceutical market by an agreement with a strong licence partner. Beactica has an established business development contact network and has already gained trust of external investors in this innovative technology.

The problem of cancer is growing dramatically and has been highlighted in the recent policy focus by the European Commission and the World Health Organisation. In this light, Beactica is assured of the significant impact the LSD1 knockdown innovation will have on the glioblastoma burden in Europe and worldwide.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/816185
Start date: 01-04-2018
End date: 30-09-2018
Total budget - Public funding: 71 429,00 Euro - 50 000,00 Euro
Cordis data

Original description

The goal of this project is to develop a successful treatment that combats the progression of glioblastoma and improve patients’ quality of life. Glioblastoma, the most malignant brain tumour, leads to disproportionately high morbidity in patients and impacts the economy through high mortality rates. The available treatment options are highly ineffective and pose a significant challenge to the healthcare budgets of all nations.

Beactica aims to address this challenge by developing novel compound to inhibit the overexpressed in cancers protein LSD1. Beactica’s programme is based on a verified LSD1 knockdown technique and proves markedly more effective with glioblastoma clones that are resistant to other therapeutics. This way, Beactica’s compounds effectively clear cancer cells from which brain tumour might grow anew and will reduce the risk of relapses.

This therapy will improve intervention outcomes for patients and lower additional treatment and healthcare costs including longer hospitalisation and further medical procedures. This programme is unique and there are no competitors using the same approach to treat glioblastoma by knockdown of the LSD1 protein with a small molecule.

The ultimate success of this project will depend on the generation of clinical data which will improve opportunities for out-licensing. Beactica plans to apply for SME Phase 2 grant to take the lead compound through the clinical Phase I/IIa, and then reach the pharmaceutical market by an agreement with a strong licence partner. Beactica has an established business development contact network and has already gained trust of external investors in this innovative technology.

The problem of cancer is growing dramatically and has been highlighted in the recent policy focus by the European Commission and the World Health Organisation. In this light, Beactica is assured of the significant impact the LSD1 knockdown innovation will have on the glioblastoma burden in Europe and worldwide.

Status

CLOSED

Call topic

EIC-SMEInst-2018-2020

Update Date

27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.2. INDUSTRIAL LEADERSHIP
H2020-EU.2.1. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
H2020-EU.2.1.0. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Cross-cutting calls
H2020-EIC-SMEInst-2018-2020
H2020-SMEInst-2018-2020-1
H2020-EU.2.3. INDUSTRIAL LEADERSHIP - Innovation In SMEs
H2020-EU.2.3.0. INDUSTRIAL LEADERSHIP - Innovation In SMEs - Cross-cutting calls
H2020-EIC-SMEInst-2018-2020
H2020-SMEInst-2018-2020-1
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.0. Cross-cutting call topics
H2020-EIC-SMEInst-2018-2020
H2020-SMEInst-2018-2020-1